SOX与XELOX对中国人进展期胃癌化疗效果的Meta分析

Chemotherapy Effects of SOX and XELOX in Chinese Patients with Advanced Gastric Cancer：A Meta- analysis

目的研究SOX方案和XELOX方案在中国人群中晚期胃癌化疗的疗效。方法检索PubMed、EmBase、Science Citation Index Expanded、Cochrane Library、Clinical Trials、中国知网数据库、万方数据库、维普数据库和中国临床试验注册网等发表的含有SOX方案和XELOX方案对比治疗中晚期胃癌的随机对照试验（RCT），并用RevMan软件进行Meta分析。结果纳入15篇RCT文献，共计1441位中晚期胃癌患者，两种化疔方案对疾病进展控制情况无明显差异，而SOX方案化疗后的恶心呕吐（RR=0．83，95％C10．70～0．98，I2=0％，P=0．03）和手足综合症（RR=0．67，95％CI 0．53～0．85，I2=42％，P=0．0007）发生率明显低于XE—LOX组。结论从化疗后副反应发生情况的角度来看，SOX方案优于XELOX方案。

Objective To evaluate chemotherapy effects of SOX and XELOX in Chinese patients with advanced gastric cancer. Methods PubMed, EmBase, Science Citation Index Expanded, Cochrane Library, Clinical Trials, CNKI, Wanfang Data, VIP and Chinese clinical trial registration website were searched for RCTs of SOX and XELOX on advanced gastric cancer. Revman software was used to perform a meta - analysis. Results 15 articles were included containing 1 441 advanced gastric cancer patients. There were no significant differences on treatment outcomes between the two chemotherapy regimens. However,the morbidities of nausea and vomiting（ RR = 0.83,95% CI 0.70 - 0.98 ,I2 =0% ,P =0.03）as well as hand -foot syndrome（RR =0.67,95% CI 0.53 -0.85 ,Iz =42% ,P =0. 0007） after the treatment of SOX were lower than those with XELOX. Conclusion SOX may be better than XELOX in Chinese patients with advanced gastric cancer considering side effects.